Clinical trial
Hepatitis B Virus Reactivation in Patients With Marginal Zone B-cell Lymphoma After Rituximab Containing Treatment: Consortium for Improving Survival of Lymphoma (CISL) Marginal Zone Lymphoma Cohort Study (MARCO)
NCT02732236 is registered in ClinicalTrials.gov with Dong-A University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Hepatitis B Virus Reactivation in Patients With Marginal Zone B-cell Lymphoma After Rituximab Containing Treatment: Consortium for Improving Survival of Lymphoma (CISL) Marginal Zone Lymphoma Cohort Study (MARCO)
- Lead sponsor
- Dong-A University Hospital
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- March 31, 2013
- Completion date
- February 28, 2022
- Enrollment
- 500 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.